What is Indiva?
Founded in 1979 and headquartered in Canada, Indiva operates as a cornerstone entity in the cannabis industry, specializing in high-quality manufacturing and production services. By maintaining rigorous standards for quality and innovation, the company has established itself as a reliable partner for peer entities while simultaneously building a strong consumer-facing brand. Its market position is defined by a dual-focus strategy: delivering premium consumer goods and providing essential manufacturing infrastructure to the broader sector, which allows for sustained growth and operational resilience in a highly regulated environment.
How much funding has Indiva raised?
Indiva has raised a total of $7.2M across 2 funding rounds:
Debt
$4M
Debt
$3.2M
Debt (2019): $4M with participation from Dycar Pharmaceuticals Ltd.
Debt (2020): $3.2M, investors not publicly disclosed
Key Investors in Indiva
Dycar Pharmaceuticals Ltd.
A specialized firm focused on pharmaceutical development and strategic investments within the healthcare and life sciences sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Indiva?
With the recent strategic investment, Indiva is well-positioned to accelerate its enterprise-level objectives. The company is expected to leverage this capital to optimize its supply chain, expand its manufacturing footprint, and potentially diversify its product offerings to meet evolving consumer demand. As the regulatory landscape for cannabis continues to mature, Indiva's focus on operational excellence and strategic partnerships will likely serve as a catalyst for long-term value creation. The firm remains focused on maintaining its leadership status by integrating advanced production technologies and scaling its distribution networks across key Canadian markets.
See full Indiva company page
